CareDx Congratulates Board Member Dr. Grace Colon for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List
September 27, 2022 at 10:00 am EDT
Share
BRISBANE - CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that Dr. Grace Colon, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).
'We congratulate Dr. Colon for being named a healthcare innovator by ALPFA and for her significant contribution in driving innovation to improve patient care,' said Michael D. Goldberg, Chairman of the Board, CareDx. 'As Chair of CareDx's Science and Technology Committee she has played an invaluable role in helping shape the company's innovation agenda focused on improving the transplant patient journey.'
Dr. Colon joined the CareDx Board of Directors in July 2019. She has served as President, Chief Executive Officer and Director of InCarda Therapeutics, Inc., a clinical stage company developing therapeutics for cardiovascular conditions, since 2013. In addition to her role at InCarda, she is also Executive Chairman (formerly Chief Executive Officer) of ProterixBio and sits on the boards of the MIT Corporation and the Biotechnology Innovation Organization.
About CareDx - The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
